|
1
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: Correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Moasser MM: The oncogene HER2: Its
signaling and transforming functions and its role in human cancer
pathogenesis. Oncogene. 26:6469–6487. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Harbeck N, Penault-Llorca F, Cortes J,
Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J and Cardoso F:
Breast cancer. Nat Rev Dis Primers. 5:662019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Klos KJ and O'Neill BP: Brain metastases.
Neurologist. 10:31–46. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kennecke H, Yerushalmi R, Woods R, Cheang
MC, Voduc D, Speers CH, Nielsen TO and Gelmon K: Metastatic
behavior of breast cancer subtypes. J Clin Oncol. 28:3271–3277.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Niikura N, Hayashi N, Masuda N, Takashima
S, Nakamura R, Watanabe K, Kanbayashi C, Ishida M, Hozumi Y,
Tsuneizumi M, Kondo N, et al: Treatment outcomes and prognostic
factors for patients with brain metastases from breast cancer of
each subtype: A multicenter retrospective analysis. Breast Cancer
Res Treat. 147:103–112. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fokstuen T, Wilking N, Rutqvist LE, Wolke
J, Liedberg A, Signomklao T and Fernberg JO: Radiation therapy in
the management of brain metastases from breast cancer. Breast
Cancer Res Treat. 62:211–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lin NU, Amiri-Kordestani L, Palmieri D,
Liewehr DJ and Steeg PS: CNS metastases in breast cancer: Old
challenge, new frontiers. Clin Cancer Res. 19:6404–6418. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Swain SM, Miles D, Kim SB, Im YH, Im SA,
Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, et al:
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic
breast cancer (CLEOPATRA): End-of-study results from a
double-blind, randomised, placebo-controlled, phase 3 study. Lancet
Oncol. 21:519–530. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Montemurro F, Donadio M, Clavarezza M,
Redana S, Jacomuzzi ME, Valabrega G, Danese S, Vietti-Ramus G,
Durando A, Venturini M and Aglietta M: Outcome of patients with
HER2-positive advanced breast cancer progressing during
trastuzumab-based therapy. Oncologist. 11:318–324. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cesca MG, Vian L, Cristóvão-Ferreira S,
Pondé N and de Azambuja E: HER2-positive advanced breast cancer
treatment in 2020. Cancer Treat Rev. 88:1020332020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yao X, Jiang J, Wang X, Huang C, Li D, Xie
K, Xu Q, Li H, Li Z, Lou L and Fang J: A novel humanized anti-HER2
antibody conjugated with MMAE exerts potent anti-tumor activity.
Breast Cancer Res Treat. 153:123–133. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Peng Z, Liu T, Wei J, Wang A, He Y, Yang
L, Zhang X, Fan N, Luo S, Li Z, et al: Efficacy and safety of a
novel anti-HER2 therapeutic antibody RC48 in patients with
HER2-overexpressing, locally advanced or metastatic gastric or
gastroesophageal junction cancer: A single-arm phase II study.
Cancer Commun (Lond). 41:1173–1182. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang J, Xu B, Wang W and Fang J: An
open-label, dose-escalation phase I study to evaluate RC48-ADC, a
novel antibody-drug conjugate, in patients with HER2-positive
metastatic breast cancer. J Clin Oncol. 36:1030. 2018. View Article : Google Scholar
|
|
15
|
Arian A, Dinas K, Pratilas GC and Alipour
S: The breast imaging-reporting and data system (BI-RADS) Made
Easy. Iranian J Radiol. 19:e1211552022. View Article : Google Scholar
|
|
16
|
Brierley JD, Gospodarowicz MK and
Wittekind C: TNM Classification of Malignant Tumours. 8th Edition.
Chichester: John Wiley and Sons; pp. 151–158. 2017
|
|
17
|
Nematollahy N: Response evaluation
criteria in solid tumors version 1.1. Iranian Soc Radiol. 35:46.
2019.
|
|
18
|
Gradishar WJ, Anderson BO, Abraham J, Aft
R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD,
et al: Breast cancer, version 3.2020, NCCN clinical practice
guidelines in oncology. J Natl Compr Canc Netw. 18:452–478. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Marupudi NI, Han JE, Li KW, Renard VM,
Tyler BM and Brem H: Paclitaxel: A review of adverse toxicities and
novel delivery strategies. Expert Opin Drug Saf. 6:609–621. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Norman H, Lee KT, Stearns V, Alcorn SR and
Mangini NS: Incidence and severity of myelosuppression with
palbociclib after palliative bone radiation in advanced breast
cancer: A single center experience and review of literature. Clin
Br Cancer. 22:e65–e73. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tao WY, Liang XS, Liu Y, Wang CY and Pang
D: Decrease of let-7f in low-dose metronomic Paclitaxel
chemotherapy contributed to upregulation of thrombospondin-1 in
breast cancer. Int J Biol Sci. 11:48–58. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen Q, Xia R, Zheng W, Zhang L, Li P, Sun
X and Shi J: Metronomic paclitaxel improves the efficacy of PD-1
monoclonal antibodies in breast cancer by transforming the tumor
immune microenvironment. Am J Transl Res. 12:519–530.
2020.PubMed/NCBI
|
|
23
|
Leone JP, Leone J, Zwenger AO, Iturbe J,
Leone BA and Vallejo CT: Prognostic factors and survival according
to tumour subtype in women presenting with breast cancer brain
metastases at initial diagnosis. Eur J Cancer. 74:17–25. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Assi HI, Mahmoud T, Saadeh FS and El Darsa
H: Management of leptomeningeal metastasis in breast cancer. Clin
Neurol Neurosurg. 172:151–159. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rudnicka H, Niwińska A and Murawska M:
Breast cancer leptomeningeal metastasis-the role of multimodality
treatment. J Neurooncol. 84:57–62. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bergen ES, Binter A, Starzer AM, Heller G,
Kiesel B, Tendl-Schulz K, Bago-Horvath Z, Furtner J, Leitner J,
Exner R, et al: Favourable outcome of patients with breast cancer
brain metastases treated with dual HER2 blockade of trastuzumab and
pertuzumab. Ther Adv Med Oncol. 13:175883592110090022021.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mounsey LA, Deal AM, Keith KC, Benbow JM,
Shachar SS, Zagar T, Dees EC, Carey LA, Ewend MG and Anders CK:
Changing Natural History of HER2-positive breast cancer metastatic
to the brain in the era of new targeted therapies. Clin Breast
Cancer. 18:29–37. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Evangelista L, Guarneri V and Conte PF:
18F-fluoroestradiol positron emission tomography in breast cancer
patients: Systematic review of the literature & meta-analysis.
Curr Radiopharm. 9:244–257. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kurland BF, Wiggins JR, Coche A, Fontan C,
Bouvet Y, Webner P, Divgi C and Linden HM: Whole-body
characterization of estrogen receptor status in metastatic breast
cancer with 16α-18F-Fluoro-17β-estradiol positron emission
tomography: Meta-analysis and recommendations for integration into
clinical applications. Oncologist. 25:835–844. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang J, Liu Y, Zhang Q, Feng J, Fang J,
Chen X, Han Y, Li Q, Zhang P, Yuan P, et al: RC48-ADC, a
HER2-targeting antibody-drug conjugate, in patients with
HER2-positive and HER2-low expressing advanced or metastatic breast
cancer: A pooled analysis of two studies. J Clin Oncol. 39:1022.
2021. View Article : Google Scholar
|
|
31
|
Huang L, Wang R, Xie K, Zhang J, Tao F, Pi
C, Feng Y, Gu H and Fang J: A HER2 target antibody drug conjugate
combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in
hPD-1 transgenic mouse model and contributes immune memory
formation. Br Cancer Res Treat. 191:51–61. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Staudacher AH and Brown MP: Antibody drug
conjugates and bystander killing: Is antigen-dependent
internalisation required? Br J Cancer. 117:1736–1742. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Müller P, Kreuzaler M, Khan T, Thommen DS,
Martin K, Glatz K, Savic S, Harbeck N, Nitz U, Gluz O, et al:
Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly
susceptible to CTLA-4/PD-1 blockade. Sci Transl Med.
7:315ra1882015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Müller P, Martin K, Theurich S, Schreiner
J, Savic S, Terszowski G, Lardinois D, Heinzelmann-Schwarz VA,
Schlaak M, Kvasnicka HM, et al: Microtubule-depolymerizing agents
used in antibody-drug conjugates induce antitumor immunity by
stimulation of dendritic cells. Cancer Immunol Res. 2:741–755.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li H, Yu C, Jiang J, Huang C, Yao X, Xu Q,
Yu F, Lou L and Fang J: An anti-HER2 antibody conjugated with
monomethyl auristatin E is highly effective in HER2-positive human
gastric cancer. Cancer Biol Ther. 17:346–354. 2016. View Article : Google Scholar : PubMed/NCBI
|
